Immuno-Oncology | Specialty

Novel Combination Shows Promising Responses in Pancreatic Cancer

November 12th 2017

The combination of cabiralizumab and nivolumab resulted in intriguing objective response rates in heavily pretreated patients with metastatic pancreatic cancer.

Neoadjuvant Nivolumab/Ipilimumab Combo Effective but Toxic for Melanoma

November 12th 2017

Neoadjuvant nivolumab plus ipilimumab demonstrated almost a tripling in objective response rate compared with the PD-1 inhibitor alone but at the cost of significant added grade 3 adverse events for patients with high-risk resectable melanoma.

NKTR-214/Nivolumab Combination Shows Promise in Early Study

November 12th 2017

The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab demonstrated target lesion reductions of 72% for patients with advanced cancers.

IDO Plus PD-1 Inhibitor Combo Sparks Responses in Bladder and Cervical Cancers

November 12th 2017

The combination of nivolumab and BMS-986205 generated promising response rates without increasing adverse effects in patients with advanced cervical or bladder cancers.

Nivolumab Spurs Responses in non-CRC Patients With dMMR

November 11th 2017

Nivolumab demonstrated a 24% overall response rate among patients with a range of non-colorectal cancers with mismatch repair deficiency who were identified through the NCI-MATCH trial.

Dr. Garon on Immunotherapy as Salvage Treatment for Advanced Lung Cancer

November 11th 2017

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses the possibility of administering PD1 or PD-L1 blockades as a third-line or salvage therapy for patients with advanced lung cancer.

MSI-H Experience Delivers Another Exciting Breakthrough in Immuno-Oncology

November 10th 2017

Immunotherapy is being positioned as an earlier therapeutic option for patients with high levels of microsatellite instability or mismatch repair deficiency, regardless of their tumor location, expert says.

Dr. Luke on the Future Role of Immunotherapy Combinations in Melanoma

November 10th 2017

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the future of immunotherapy combinations for patients with melanoma.

Dr. Inman on Biomarkers for Immunotherapy in Bladder Cancer

November 10th 2017

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center discusses biomarkers for immunotherapy in patients with bladder cancer.

Combinations Required to Further Advance Adoptive T-Cell Therapy

November 10th 2017

A variety of adoptive T-cell therapy strategies have shown promise in clinical studies with recent FDA approvals granted to CAR-modified T-cell therapies, representing the potential for future combination strategies.

Immunotherapy Impact Extends to Mesothelioma

November 9th 2017

Gerard Zalcman, MD, discusses the promise of immunotherapy in patients with mesothelioma.

Expert Discusses Durvalumab and Expanding Role of Immunotherapy in NSCLC

November 9th 2017

Marina C. Garassino, MD, discusses the evolving paradigm of immunotherapy in NSCLC, with a specific focus on durvalumab and the role of combination therapy.

Dr. Simon on Durvalumab for Patients With Lung Cancer

November 7th 2017

George R. Simon, MD, FACP, FCCP, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses durvalumab (Imfinzi) for patients with lung cancer.

Checkpoint Inhibitors Herald a New Era for Treating Urothelial Cancer

November 7th 2017

Decades of clinical trials exploring modifications of cytotoxic regimens, including the use of different or more drugs, demonstrated that a therapeutic plateau had been reached with conventional chemotherapeutic agents, highlighting the need for novel approaches in urothelial carcinoma.

Immunotherapy Continues to Impress in GU Malignancies

November 7th 2017

Andrea Apolo, MD, discusses the combination of cabozantinib plus nivolumab and ipilimumab, as well as the latest data on avelumab in urothelial carcinoma.

Nivolumab Sustains Survival Benefit in RCC at 3 Years

November 7th 2017

Nivolumab reduced the risk of death by 26% compared with everolimus in patients with previously treated advanced renal cell carcinoma.

Dr. Zamarin on the Role of Pembrolizumab in Endometrial Cancer

November 7th 2017

Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of pembrolizumab (Keytruda) for patients with endometrial cancer.

Dr. Mikhail on Ongoing Clinical Trials for Patients With Myeloma

November 7th 2017

Sameh Mikhail, MD, medical oncologist, The Mark H. Zangmeister Cancer Center, discusses ongoing clinical trials for patients with myeloma.

Pembrolizumab Demonstrates Safety and Efficacy in Cervical Cancer

November 4th 2017

In phase Ib results from the KEYNOTE-028 trial, pembrolizumab (Keytruda) was found to be active in cervical cancer while demonstrating safety results similar to previous studies with the PD-1 inhibitor.

NICE Recommends Frontline Atezolizumab for Advanced Urothelial Cancer

November 2nd 2017

The UK’s National Institute for Health and Care Excellence is recommending the use of atezolizumab for treatment-naïve patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-based therapy.